INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...

Regeneron Pharmaceuticals Inc.'s stock rose 3% early Tuesday, after the company posted better-than-expected fourth-quarter ...

Rheumatoid arthritis (RA) is an autoimmune disorder affecting millions worldwide, causing chronic inflammation, debilitating ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

VANCOUVER - InMed Pharmaceuticals Inc. (NASDAQ: INM), a small-cap biotech company with a market capitalization of $2.21 million, has announced the selection of an intravitreal (IVT) formulation, ...

Bajaj Health has also extended the offer for Pimavanserin to several leading pharma companies to ensure availability in ...

Journey Medical's future hinges on Emrosi, a new formulation of minocycline for rosacea, showing superior efficacy. Read why ...